Emerging Treatments | Lung Cancer - World Medical Innovation Forum

Lung cancer is the third most common cancer in the U.S. and the leading cause of cancer death. While much therapeutic development is underway, insights from lung cancer research may also benefit other solid tumors. This session will explore the evolving treatment landscape: including bispecific antibodies (e.g., PD-1 x VEGF, EGFR x MET, PD-1 x TIGIT); novel ADCs (e.g. TROP-2 class of agents), checkpoint inhibitors beyond PD-1/-L1 and CTLA-4, such as TIGIT, LAG-3, and TIM-3; and late-stage cancer vaccines.

Moderators

Tim Anderson, MD,

Pharmaceutical Analyst, BofA Securities

Alec Stranahan

US SMid-Cap Biotechnology Analyst BofA Securities

Speaker

Justin Gainor MD

Division Chief, Solid Tumor Medical Oncology Mass General Brigham Cancer Institute

Associate Professor of Medicine, Harvard Medical School

Rebecca Heist MD

Physician-in-Chief Mass General Brigham Cancer Institute

Professor of Medicine, Harvard Medical School

Zofia Piotrowska MD

Clinical Director, Thoracic Oncology Group Mass General Brigham Cancer Institute

Assistant Professor of Medicine, Harvard Medical School